marketnetra
Sign inStart free

Eris Lifesciences Limited

NSE: ERISHealthcare

Eris Lifesciences Limited Share Price & Analysis

₹1175.40−1.92%Updated 28 Oct 2026, 03:30 pm IST
LTP
₹1175.40−1.92%
Open
₹1215.50
High
₹1215.50
Low
₹1163.20
Close
₹1175.40
52W High
₹1740.00
52W Low
₹1069.00
Volume
64K
Lot Size
1
Sector
Healthcare
Market Cap
₹15K Cr
Face Value
₹1
Mid CapNIFTY 500Nifty Smallcap 250

Price Chart

Candle
Range

Fundamentals

P/E
23.20
Sector P/E
50.20
P/B
6.00
EPS
₹45.21
ROE
18.70%
ROCE
14.10%
D/E Ratio
0.61
Div Yield
0.66%
Book Value
₹282.00

Strengths

  • Strong return on equity (ROE 18.7%)
  • Attractively valued vs sector (P/E 23.2x vs industry 50.2x)

Concerns

    Peer Comparison

    CompanyCMPMkt CapP/EP/BROE %ROCE %D/E
    SUNPHARMA
    Sun Pharmaceutical Industries Limited
    ₹1,758
    		₹4.2L Cr33.25.051620.50.07
    DIVISLAB
    Divi's Laboratories Limited
    ₹9,559
    		₹2.4L Cr79.815.1516.5220.01
    TORNTPHARM
    Torrent Pharmaceuticals Limited
    ₹4,557
    		₹1.7L Cr79.39.4327.415.20.77
    ZYDUSLIFE
    Zydus Lifesciences Limited
    ₹1,176
    		₹1.1L Cr23.14.3721.221.10.38
    APOLLOHOSP
    Apollo Hospitals Enterprise Limited
    ₹8,137
    		₹1.1L Cr52.812.3521.217.40.88
    CIPLA
    Cipla Limited
    ₹1,366
    		₹1.1L Cr30.23.2111.615.50.01
    LAURUSLABS
    Laurus Labs Limited
    ₹2,182
    		₹1.1L Cr97.422.2218.317.80.46

    Showing 7 peers in the same sector · Sorted by market cap

    Shareholding Pattern

    ERIS · as of Mar 2026

    Promoters54.85%
    FII8.43%0.07pp
    DII18.07%
    Public18.64%0.09pp
    CategoryDec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
    Promoters54.90%54.90%54.88%54.87%54.86%54.85%
    FII13.13%14.27%14.59%8.01%8.36%8.43%
    DII14.55%15.63%16.23%18.64%18.07%18.07%
    Public17.41%15.20%14.30%18.47%18.73%18.64%

    Corporate Events

    To consider and approve the financial results for the period ended September 30, 2026

    Results25 Oct 2026

    To consider and approve the financial results for the period ended Jun 30, 2026

    Results28 Jul 2026

    Interim Dividend - Rs 7.21 Per Share

    Dividend28 May 2026

    Interim Dividend - Rs 7.35 Per Share

    Dividend12 Feb 2025

    Annual General Meeting

    AGM16 Sept 2024

    Annual General Meeting

    AGM14 Sept 2023

    Latest News

    All news

    Eris Lifesciences reports Q2FY26 financial results

    *Eris Lifesciences reports Q2FY26 financial results* as per its board meeting outcome. The company has filed its financial results for the quarter ended September 30, 2026, with the exchange. Key performance metrics including revenue and net profit will be closely watched by traders for guidance on F&O positions. **₹** figures and margin trends may influence near-term trading sentiment. 📊 *STOCKS:* $ERIS | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #ErisLifesciences

    NSE Filing2d ago
    High Impact

    Eris Lifesciences announces board meeting outcomes

    *Eris Lifesciences announces board meeting outcomes.* The company disclosed outcomes from its August 31, 2026, board meeting, covering routine corporate matters. No **major** financial figures or strategic shifts were disclosed. The filing appears to be procedural in nature. 📊 *STOCKS:* $ERIS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pharma

    NSE Filing31 Aug
    High Impact

    Eris Lifesciences reports Q1FY26 financial results

    *Eris Lifesciences reports Q1FY26 financial results*. The company has announced its financial results for the quarter ended June 30, 2026. Key performance metrics and **revenue** and **profit** figures will impact near-term trading sentiment. Investors await guidance and margin trends for future outlook. 📊 *STOCKS:* $ERIS | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #ErisLifesciences

    NSE Filing29 Jul
    High Impact

    Eris Lifesciences shares to watch on investor presentation

    *Eris Lifesciences shares to watch on investor presentation.* The company released an investor presentation, offering insights into business strategy and financial performance. No major announcements or **₹** figures disclosed. Likely a routine update ahead of earnings or roadshows. 📊 *STOCKS:* $ERIS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorPresentation

    NSE Filing2d ago
    Low Impact

    Eris Lifesciences to hold shareholder meeting on Sep 25, 2026

    *Eris Lifesciences to hold shareholder meeting on Sep 25, 2026.* The event is a routine corporate disclosure with no immediate financial implications. No material business decisions or announcements are indicated. Such meetings typically address statutory requirements. 📊 *STOCKS:* $ERIS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ShareholdersMeeting

    NSE Filing25 Sept
    Low Impact

    Eris Lifesciences to host analyst and investor meet

    *Eris Lifesciences to host analyst and investor meet.* The company has scheduled a conference call for institutional investors and analysts. **No financial updates or major announcements** were disclosed in the filing. It is primarily a routine engagement to discuss business performance and outlook. 📊 *STOCKS:* $ERIS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pharma

    NSE Filing7 Sept
    Low Impact

    Eris Lifesciences to host analyst meet

    *Eris Lifesciences to host analyst and institutional investor meet.* The event is scheduled to provide updates on company performance and strategy. **No financial figures or major announcements** were disclosed in the filing. It is primarily an information session for stakeholders. 📊 *STOCKS:* ERIS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pharma

    NSE Filing10 Aug
    Low Impact

    Eris Lifesciences hosts analyst and investor meet

    *Eris Lifesciences hosts analyst and investor meet.* The company provided updates during a recent conference call with institutional investors. No major financial announcements or guidance revisions were disclosed. The event focused on ongoing business operations and market outlook. 📊 *STOCKS:* $ERIS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pharma

    NSE Filing4 Aug
    Low Impact

    Eris Lifesciences to host analyst and investor meet

    *Eris Lifesciences to host analyst and investor meet.* The company has scheduled a conference call for institutional investors and analysts. This event aims to provide updates on business performance and strategy. No financial figures or major announcements were disclosed. 📊 *STOCKS:* ERIS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Earnings

    NSE Filing30 Jul
    Low Impact

    Eris Lifesciences allots 4,816 shares under employee stock plan

    *Eris Lifesciences allots 4,816 shares under employee stock plan.* The company issued **4,816** equity shares pursuant to its ESOP/ESOS/ESPS scheme. The allotment is part of ongoing employee compensation initiatives. Such small-scale issuances have minimal impact on shareholding or earnings. 📊 *STOCKS:* $ERIS | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ESOP

    NSE Filing30 Jul
    Low Impact

    Financials

    Quarterly Results

    MetricMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
    Revenue
    ₹757 Cr
    6.2%
    ₹807 Cr
    1.9%
    ₹792 Cr
    2.5%
    ₹773 Cr
    9.6%
    ₹705 Cr
    3.0%
    ₹727 Cr
    1.9%
    ₹741 Cr
    2.9%
    ₹720 Cr
    Op. Profit
    ₹272 Cr
    3.5%
    ₹282 Cr
    2.1%
    ₹288 Cr
    4.0%
    ₹277 Cr
    9.9%
    ₹252 Cr
    0.8%
    ₹250 Cr
    5.7%
    ₹265 Cr
    6.0%
    ₹250 Cr
    OPM
    36.0%
    2.9%
    35.0%
    2.8%
    36.0%
    0.0%
    36.0%
    0.0%
    36.0%
    5.9%
    34.0%
    5.6%
    36.0%
    2.9%
    35.0%
    Net Profit
    ₹279 Cr
    156.0%
    ₹109 Cr
    18.7%
    ₹134 Cr
    7.2%
    ₹125 Cr
    22.5%
    ₹102 Cr
    17.2%
    ₹87 Cr
    9.4%
    ₹96 Cr
    6.7%
    ₹90 Cr
    EPS (₹)
    20.33
    177.7%
    7.32
    17.0%
    8.82
    1.8%
    8.66
    25.7%
    6.89
    12.0%
    6.15
    8.6%
    6.73
    10.0%
    6.12

    Values in ₹ Cr · Source: Screener.in

    Annual Profit & Loss

    MetricMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Revenue
    ₹3.1K Cr
    8.1%
    ₹2.9K Cr
    44.1%
    ₹2.0K Cr
    19.2%
    ₹1.7K Cr
    25.1%
    ₹1.3K Cr
    11.1%
    ₹1.2K Cr
    12.8%
    ₹1.1K Cr
    9.4%
    ₹982 Cr
    14.7%
    ₹856 Cr
    14.1%
    ₹750 Cr
    Expenses
    ₹2.0K Cr
    7.1%
    ₹1.9K Cr
    40.8%
    ₹1.3K Cr
    16.2%
    ₹1.1K Cr
    33.6%
    ₹858 Cr
    9.9%
    ₹781 Cr
    11.3%
    ₹702 Cr
    10.2%
    ₹637 Cr
    19.5%
    ₹533 Cr
    11.0%
    ₹480 Cr
    Op. Profit
    ₹1.1K Cr
    10.0%
    ₹1.0K Cr
    50.4%
    ₹677 Cr
    25.6%
    ₹539 Cr
    10.2%
    ₹489 Cr
    13.5%
    ₹431 Cr
    15.9%
    ₹372 Cr
    7.8%
    ₹345 Cr
    7.1%
    ₹322 Cr
    19.7%
    ₹269 Cr
    OPM
    36.0%
    2.9%
    35.0%
    2.9%
    34.0%
    6.3%
    32.0%
    11.1%
    36.0%
    0.0%
    36.0%
    2.9%
    35.0%
    0.0%
    35.0%
    7.9%
    38.0%
    5.6%
    36.0%
    Other Income
    ₹-9 Cr
    150.0%
    ₹18 Cr
    18.2%
    ₹22 Cr
    144.4%
    ₹9 Cr
    59.1%
    ₹22 Cr
    144.4%
    ₹9 Cr
    25.0%
    ₹12 Cr
    61.3%
    ₹31 Cr
    19.2%
    ₹26 Cr
    4.0%
    ₹25 Cr
    Interest
    ₹193 Cr
    16.5%
    ₹231 Cr
    171.8%
    ₹85 Cr
    226.9%
    ₹26 Cr
    550.0%
    ₹4 Cr
    100.0%
    ₹2 Cr
    0.0%
    ₹2 Cr
    91.3%
    ₹23 Cr
    109.1%
    ₹11 Cr
    1000.0%
    ₹1 Cr
    Depreciation
    ₹280 Cr
    11.1%
    ₹315 Cr
    72.1%
    ₹183 Cr
    56.4%
    ₹117 Cr
    80.0%
    ₹65 Cr
    51.2%
    ₹43 Cr
    14.0%
    ₹50 Cr
    38.9%
    ₹36 Cr
    38.5%
    ₹26 Cr
    13.0%
    ₹23 Cr
    PBT
    ₹639 Cr
    30.7%
    ₹489 Cr
    13.5%
    ₹431 Cr
    6.4%
    ₹405 Cr
    8.4%
    ₹442 Cr
    12.2%
    ₹394 Cr
    19.0%
    ₹331 Cr
    4.4%
    ₹317 Cr
    1.6%
    ₹312 Cr
    15.6%
    ₹270 Cr
    Tax %
    -1.0%
    104.3%
    23.0%
    187.5%
    8.0%
    0.0%
    8.0%
    0.0%
    8.0%
    20.0%
    10.0%
    9.1%
    11.0%
    37.5%
    8.0%
    33.3%
    6.0%
    33.3%
    9.0%
    Net Profit
    ₹648 Cr
    72.8%
    ₹375 Cr
    5.5%
    ₹397 Cr
    6.1%
    ₹374 Cr
    7.9%
    ₹406 Cr
    14.4%
    ₹355 Cr
    19.5%
    ₹297 Cr
    2.1%
    ₹291 Cr
    1.4%
    ₹295 Cr
    19.4%
    ₹247 Cr
    EPS (₹)
    44.72
    73.1%
    25.84
    10.3%
    28.82
    2.6%
    28.1
    6.0%
    29.88
    14.2%
    26.16
    19.8%
    21.84
    3.3%
    21.15
    1.1%
    21.39
    19.2%
    17.95
    Div Payout
    16.0%
    42.9%
    28.0%
    0.0%
    100.0%
    26.0%
    30.0%
    20.0%
    4.8%
    21.0%
    61.5%
    13.0%
    0.0%
    0.0%
    0.0%

    Values in ₹ Cr · Source: Screener.in

    Balance Sheet

    ItemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Liabilities
    Equity Capital
    ₹14 Cr
    0.0%
    ₹14 Cr
    0.0%
    ₹14 Cr
    0.0%
    ₹14 Cr
    0.0%
    ₹14 Cr
    0.0%
    ₹14 Cr
    0.0%
    ₹14 Cr
    0.0%
    ₹14 Cr
    0.0%
    ₹14 Cr
    0.0%
    ₹14 Cr
    Reserves
    ₹3.9K Cr
    36.9%
    ₹2.8K Cr
    10.4%
    ₹2.6K Cr
    17.9%
    ₹2.2K Cr
    15.1%
    ₹1.9K Cr
    21.2%
    ₹1.6K Cr
    21.8%
    ₹1.3K Cr
    12.8%
    ₹1.1K Cr
    34.1%
    ₹848 Cr
    53.3%
    ₹553 Cr
    Borrowings
    ₹2.4K Cr
    4.8%
    ₹2.5K Cr
    10.9%
    ₹2.8K Cr
    217.1%
    ₹877 Cr
    944.0%
    ₹84 Cr
    1100.0%
    ₹7 Cr
    ₹0 Cr
    100.0%
    ₹176 Cr
    53.3%
    ₹377 Cr
    37600.0%
    ₹1 Cr
    Other Liabilities
    ₹861 Cr
    39.2%
    ₹1.4K Cr
    3.6%
    ₹1.4K Cr
    305.3%
    ₹337 Cr
    44.6%
    ₹233 Cr
    15.3%
    ₹202 Cr
    1.5%
    ₹205 Cr
    17.1%
    ₹175 Cr
    2.9%
    ₹170 Cr
    37.1%
    ₹124 Cr
    Total Liabilities
    ₹7.1K Cr
    5.6%
    ₹6.7K Cr
    0.2%
    ₹6.7K Cr
    97.5%
    ₹3.4K Cr
    53.2%
    ₹2.2K Cr
    24.7%
    ₹1.8K Cr
    18.8%
    ₹1.5K Cr
    0.0%
    ₹1.5K Cr
    6.7%
    ₹1.4K Cr
    103.5%
    ₹692 Cr
    Assets
    Fixed Assets
    ₹5.2K Cr
    2.2%
    ₹5.3K Cr
    22.9%
    ₹4.3K Cr
    68.2%
    ₹2.6K Cr
    179.7%
    ₹918 Cr
    7.5%
    ₹854 Cr
    2.4%
    ₹875 Cr
    15.0%
    ₹761 Cr
    1.3%
    ₹771 Cr
    232.3%
    ₹232 Cr
    CWIP
    ₹171 Cr
    155.2%
    ₹67 Cr
    235.0%
    ₹20 Cr
    9.1%
    ₹22 Cr
    18.5%
    ₹27 Cr
    1250.0%
    ₹2 Cr
    50.0%
    ₹4 Cr
    33.3%
    ₹3 Cr
    ₹0 Cr
    ₹0 Cr
    Investments
    ₹62 Cr
    7.5%
    ₹67 Cr
    318.8%
    ₹16 Cr
    56.8%
    ₹37 Cr
    92.9%
    ₹520 Cr
    76.9%
    ₹294 Cr
    276.9%
    ₹78 Cr
    78.1%
    ₹356 Cr
    2.5%
    ₹365 Cr
    20.5%
    ₹303 Cr
    Other Assets
    ₹1.7K Cr
    30.2%
    ₹1.3K Cr
    45.1%
    ₹2.4K Cr
    203.8%
    ₹783 Cr
    2.9%
    ₹761 Cr
    19.7%
    ₹636 Cr
    16.9%
    ₹544 Cr
    42.0%
    ₹383 Cr
    41.3%
    ₹271 Cr
    72.6%
    ₹157 Cr
    Total Assets
    ₹7.1K Cr
    5.6%
    ₹6.7K Cr
    0.2%
    ₹6.7K Cr
    97.5%
    ₹3.4K Cr
    53.2%
    ₹2.2K Cr
    24.7%
    ₹1.8K Cr
    18.8%
    ₹1.5K Cr
    0.0%
    ₹1.5K Cr
    6.7%
    ₹1.4K Cr
    103.5%
    ₹692 Cr

    Values in ₹ Cr · Source: Screener.in

    Cash Flow Statement

    ItemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Operating CF
    ₹538 Cr
    49.5%
    ₹1.1K Cr
    119.1%
    ₹486 Cr
    66.4%
    ₹292 Cr
    22.8%
    ₹378 Cr
    0.8%
    ₹375 Cr
    38.4%
    ₹271 Cr
    21.5%
    ₹223 Cr
    5.1%
    ₹235 Cr
    17.5%
    ₹200 Cr
    Investing CF
    ₹-369 Cr
    373.1%
    ₹-78 Cr
    95.7%
    ₹-1.8K Cr
    87.5%
    ₹-975 Cr
    204.7%
    ₹-320 Cr
    0.9%
    ₹-323 Cr
    362.6%
    ₹123 Cr
    2560.0%
    ₹-5 Cr
    99.2%
    ₹-590 Cr
    220.7%
    ₹-184 Cr
    Financing CF
    ₹-314 Cr
    64.4%
    ₹-881 Cr
    163.8%
    ₹1.4K Cr
    100.6%
    ₹688 Cr
    1628.9%
    ₹-45 Cr
    45.1%
    ₹-82 Cr
    75.5%
    ₹-335 Cr
    51.6%
    ₹-221 Cr
    160.9%
    ₹363 Cr
    1612.5%
    ₹-24 Cr
    Net Cash Flow
    ₹-145 Cr
    238.1%
    ₹105 Cr
    176.3%
    ₹38 Cr
    660.0%
    ₹5 Cr
    64.3%
    ₹14 Cr
    146.7%
    ₹-30 Cr
    150.0%
    ₹60 Cr
    2100.0%
    ₹-3 Cr
    137.5%
    ₹8 Cr
    200.0%
    ₹-8 Cr
    Free Cash Flow
    ₹241 Cr
    73.5%
    ₹910 Cr
    154.9%
    ₹357 Cr
    164.9%
    ₹-550 Cr
    313.2%
    ₹258 Cr
    26.3%
    ₹350 Cr
    180.0%
    ₹125 Cr
    32.8%
    ₹186 Cr
    11.4%
    ₹210 Cr
    40.0%
    ₹150 Cr

    Values in ₹ Cr · Source: Screener.in

    Key Ratios History

    MetricMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Debtor Days
    79d
    36.2%
    58d
    24.7%
    77d
    22.2%
    63d
    43.2%
    44d
    4.8%
    42d
    20.8%
    53d
    71.0%
    31d
    10.7%
    28d
    16.7%
    24d
    Inventory Days
    200d
    17.0%
    171d
    6.0%
    182d
    33.8%
    136d
    18.1%
    166d
    14.5%
    145d
    2.0%
    148d
    24.5%
    196d
    10.1%
    178d
    8.7%
    195d
    Days Payable
    151d
    11.2%
    170d
    19.0%
    210d
    62.8%
    129d
    22.3%
    166d
    5.7%
    157d
    26.3%
    213d
    6.5%
    200d
    19.0%
    247d
    84.3%
    134d
    Cash Conv. Cycle
    129d
    118.6%
    59d
    22.9%
    48d
    31.4%
    70d
    59.1%
    44d
    46.7%
    30d
    350.0%
    -12d
    142.9%
    28d
    170.0%
    -40d
    147.6%
    84d
    Working Capital Days
    -71d
    44.9%
    -49d
    83.4%
    -296d
    692.0%
    50d
    33.3%
    75d
    17.2%
    64d
    8.5%
    59d
    447.1%
    -17d
    30.8%
    -13d
    156.5%
    23d
    ROCE
    14.0%
    16.7%
    12.0%
    9.1%
    11.0%
    35.3%
    17.0%
    32.0%
    25.0%
    7.4%
    27.0%
    8.0%
    25.0%
    3.8%
    26.0%
    23.5%
    34.0%
    43.3%
    60.0%

    Source: Screener.in · Lower days = better efficiency

    About Eris Lifesciences Limited

    ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products.[1]

    HealthcarePharmaceuticals & Biotechnology

    Related Analysis

    Same Sector

    ALKEMAlkem Laboratories LimitedNeutralAPOLLOHOSPApollo Hospitals Enterprise LimitedNeutralAUROPHARMAAurobindo Pharma LimitedNeutralBIOCONBiocon LimitedNeutralCIPLACipla LimitedNeutral

    Frequently Asked Questions

    What is Eris Lifesciences Limited share price today?
    Eris Lifesciences Limited (ERIS) is currently trading at ₹1,175.4 on NSE, down 1.92% as of the last market session. Prices update daily after market close on MarketNetra.
    Is Eris Lifesciences Limited available in F&O (Futures & Options)?
    Yes, Eris Lifesciences Limited (ERIS) is part of the NSE F&O segment with a lot size of 1 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
    What is Eris Lifesciences Limited 52-week high and low?
    Eris Lifesciences Limited's 52-week high is ₹1,740 and the 52-week low is ₹1,069. The current price of ₹1,175.4 is 32.4% below the 52W high.
    What is Eris Lifesciences Limited P/E ratio?
    Eris Lifesciences Limited's current P/E ratio is 23.2. This indicates the market is paying ₹23.2 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
    How to trade Eris Lifesciences Limited options?
    Eris Lifesciences Limited options are traded on NSE with monthly expiry contracts (lot size: 1 shares). To trade ERIS options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.